378 related articles for article (PubMed ID: 30165195)
1. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
3. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
4. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.
Dalal K; Che M; Que NS; Sharma A; Yang R; Lallous N; Borgmann H; Ozistanbullu D; Tse R; Ban F; Li H; Tam KJ; Roshan-Moniri M; LeBlanc E; Gleave ME; Gewirth DT; Dehm SM; Cherkasov A; Rennie PS
Mol Cancer Ther; 2017 Oct; 16(10):2281-2291. PubMed ID: 28775145
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
6. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
8. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
9. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
10. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Chan SC; Selth LA; Li Y; Nyquist MD; Miao L; Bradner JE; Raj GV; Tilley WD; Dehm SM
Nucleic Acids Res; 2015 Jul; 43(12):5880-97. PubMed ID: 25908785
[TBL] [Abstract][Full Text] [Related]
11. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
[TBL] [Abstract][Full Text] [Related]
12. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
Dalal K; Morin H; Ban F; Shepherd A; Fernandez M; Tam KJ; Li H; LeBlanc E; Lack N; Prinz H; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Sep; 157():1164-1173. PubMed ID: 30193215
[TBL] [Abstract][Full Text] [Related]
13. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
14. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer.
Yi Q; Liu W; Seo JH; Su J; Alaoui-Jamali MA; Luo J; Lin R; Wu JH
Mol Cancer Ther; 2023 May; 22(5):570-582. PubMed ID: 37139712
[TBL] [Abstract][Full Text] [Related]
17. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
18. Role of androgen receptor splice variants, their clinical relevance and treatment options.
Wach S; Taubert H; Cronauer M
World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules.
Masoodi KZ; Xu Y; Dar JA; Eisermann K; Pascal LE; Parrinello E; Ai J; Johnston PA; Nelson JB; Wipf P; Wang Z
Mol Cancer Ther; 2017 Oct; 16(10):2120-2129. PubMed ID: 28655783
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]